CVD screening in low-risk, asymptomatic adults: Clinical trials needed

Tamar S. Polonsky, Philip Greenland*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

26 Scopus citations

Abstract

The public-health impact of cardiovascular disease (CVD) remains high despite advances in prevention and treatment. Large numbers of cardiovascular events occur in asymptomatic people who do not have a high level of risk from single risk factors or in terms of multivariable risk scores. Novel risk markers, such as carotid intima-media thickness, high-sensitivity measurement of C-reactive protein, coronary artery calcium score, and genetic risk scores have been suggested as new ways to identify candidates for primary prevention of CVD through intensive risk-factor modification. Yet, many questions remain unanswered. Can these novel markers be used to identify adults who will benefit from statin therapy? How will novel markers affect medication adherence? Is screening using these markers cost-effective? Our opinion is that clinical trials of one or more of these novel tests, combined with monitoring of traditional risk factors, are needed in asymptomatic, low-risk populations.

Original languageEnglish (US)
Pages (from-to)599-604
Number of pages6
JournalNature Reviews Cardiology
Volume9
Issue number10
DOIs
StatePublished - Oct 1 2012

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'CVD screening in low-risk, asymptomatic adults: Clinical trials needed'. Together they form a unique fingerprint.

Cite this